Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) plus everolimus (EVE) versus sunitinib (SUN) treatment arms.

被引：1
|
作者：
Hutson, Thomas E.
Choueiri, Toni K.
Motzer, Robert J.
Rha, Sun Young
Alyasova, Anna
Merchan, Jaime R.
Gurney, Howard
Peer, Avivit
Takagi, Toshio
Porta, Camillo
Powles, Thomas
Grunwald, Viktor
De Giorgi, Ugo
Vaishampayan, Ulka N.
Schmidinger, Manuela
Glen, Hilary
Rodriguez-Lopez, Karla
Xing, Dongyuan
Dutta, Lea
Eto, Masatoshi
机构：
[1] Texas Oncol, Dallas, TX USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[5] Prevoljskiy Reg Med Ctr, Novgorod, Russia
[6] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[7] Macquarie Univ Hosp, Sydney, NSW, Australia
[8] Rambam Hlth Care Campus, Haifa, Israel
[9] Tokyo Womens Med Univ, Tokyo, Japan
[10] San Matteo Univ Hosp Fdn, Pavia, Italy
[11] Royal Free NHS Trust, London, England
[12] Univ Hosp Essen, Essen, Germany
[13] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[14] Univ Michigan, Ann Arbor, MI 48109 USA
[15] Med Univ Vienna, Vienna, Austria
[16] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Eisai Inc, Woodcliff Lake, NJ USA
[19] Kyushu Univ, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4562
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4562
引用
收藏
页数：3
相关论文
共 48 条
  • [1] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
    Gruenwald, V
    Hutson, T.
    Choueiri, T. K.
    Motzer, R.
    Rha, S. Y.
    Alyasova, A.
    Merchan, J.
    Gurney, H.
    Peer, A.
    Takagi, T.
    Porta, C.
    Powles, T.
    De Giorgi, U.
    Vaishampayan, U.
    Schmidinger, M.
    Glen, H.
    Rodriguez-Lopez, K.
    Xing, D.
    Dutta, L.
    Eto, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 275
  • [2] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) plus pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
    Grunwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Gordoa, Teresa Alonso
    Eto, Masatoshi
    Hutson, Thomas E.
    Motzer, Robert J.
    Winquist, Eric
    Maroto-Rey, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    Smith, Alan D.
    Porta, Camillo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Mendez Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Merchan, Jaime R.
    Smith, Alan D.
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing Dongyuan
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, Camillo G.
    Eto, Masatoshi
    Motzer, Robert J.
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    He, Cixin Steven
    Perini, Rodolfo
    Mody, Kalgi
    McKenzie, Jodi
    Ebaid, Basant
    Choueiri, Toni
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
  • [5] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
    Grunwald, Viktor
    Powles, Thomas
    Choueiri, Toni K.
    Hutson, Thomas E.
    Porta, Camillo
    Eto, Masatoshi
    Sternberg, Cora N.
    Rha, Sun Young
    He, Cixin S.
    Dutcus, Corina E.
    Smith, Alan
    Dutta, Lea
    Mody, Kalgi
    Motzer, Robert J.
    [J]. FUTURE ONCOLOGY, 2019, 15 (09) : 929 - 941
  • [7] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
  • [8] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Wang, Jinyi
    Pan, Janice
    Asfaw, Alemseged Ayele
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Gruenwald, V.
    Powles, T.
    Eto, M.
    Kopyltsov, E.
    Rha, S. Y.
    Porta, C.
    Motzer, R.
    Hutson, T. E.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Winquist, E.
    Goh, J. C.
    Maroto, P.
    Buchler, T.
    Takagi, T.
    Burgents, J. E.
    Perini, R.
    He, C.
    Okpara, C. E.
    McKenzie, J.
    Choueiri, T. K.
    [J]. ONKOUROLOGIYA, 2024, 20 (01): : 24 - 35
12345